Daiwa Securities Group
ABOS icon

Daiwa Securities Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Daiwa Securities Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-165
Closed -$1K – 1317
2023
Q3 		$1K Hold
165
– – ﹤0.01% 1232
2023
Q2 		$1K Hold
165
– – ﹤0.01% 1255
2023
Q1 		$1K Hold
165
– – ﹤0.01% 1234
2022
Q4 		$1K Buy
+165
New +$1.11K ﹤0.01% 1250

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Daiwa Securities Group's ABOS Position: Q4 2023 in Review

Daiwa Securities Group sold out of Acumen Pharmaceuticals (ABOS) in Q4 2023, closing a stake of 165 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in ABOS in Q4 2022 and held it in 4 quarters. The position peaked at $1K in Q3 2023. 67 funds tracked by Wall St. Rank hold ABOS as of Q4 2023.

  • Daiwa Securities Group reported no remaining Acumen Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 165 Acumen Pharmaceuticals shares in Q4 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Daiwa Securities Group's Acumen Pharmaceuticals position peaked at $1K in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.